As Chemocentryx INC (CCXI) Shares Rose, Shareholder Bvf INC Decreased Stake by $5.02 Million

June 27, 2018 - By Don Salinas

ChemoCentryx, Inc. (NASDAQ:CCXI) Corporate LogoDuring Q1 2018 the big money sentiment decreased to 1. That’s change of 0.30, from 2017Q4’s 1.3. 10 investors sold all, 36 reduced holdings as CCXI ratio is negative. 22 increased stakes while 24 funds bought stakes. Funds hold 24.22 million shares thus 3.03% more from 2017Q4’s 23.51 million shares. Wells Fargo & Mn reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Fernwood Mgmt Ltd Liability Company accumulated 0.08% or 10,000 shs. Sei Invests holds 0% of its capital in ChemoCentryx, Inc. (NASDAQ:CCXI) for 2,817 shs. Moreover, Bvf Il has 9.93% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Moreover, Carmignac Gestion has 0.04% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). California Pub Employees Retirement System holds 0% or 62,800 shs in its capital. Blackrock reported 2.57 million shs stake. Banque Pictet & Cie Sa, Switzerland-based fund reported 54,178 shs. The Illinois-based Citadel Advisors Limited Liability Corporation has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Ellington Management Grp Incorporated Llc stated it has 0.02% of its capital in ChemoCentryx, Inc. (NASDAQ:CCXI). Ameritas Invest Partners has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Barclays Public Limited Com invested in 0% or 13,066 shs. Moreover, Bridgeway Mngmt has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Northern Trust Corp stated it has 276,280 shs or 0% of all its holdings. 37,591 are held by Alps Advsrs.

CCXI registered $6.04 million net activity with 0 insider buys and 8 selling transactions since May 1, 2018. Shares for $590,637 were sold by Cappel Markus J. on Wednesday, May 16. On Tuesday, May 15 200,000 shs were sold by Schall Thomas J., worth $2.36M.

The holdings In Chemocentryx Inc (CCXI) was decreased held by Bvf Inc. According to 2018Q1 Securities and Exchange form the decrease is 5.09%. The company’s stock rose 32.26% while stock markets declined as Bvf Inc sold 386,100 shares. At the end of 2018Q1, the hedge fund held 7.20M shares of the health care company, valued at $97.94M, down from 7.59M at the end of the previous reported quarter. For a total of 1.95 million shares it increased its holding in Corvus Pharmaceuticals Inc by 1.49 million shares in the quarter, and has risen its stake in Immune Design Corp (NASDAQ:IMDZ).

Earnings report for ChemoCentryx, Inc. (NASDAQ:CCXI) is anticipated on August, 14., Zacks reports. Analysts predict $-0.25 earnings per share, which is $0.06 down or 31.58 % from 2017’s $-0.19 earnings per share. Analysts at Wall Street see ChemoCentryx, Inc.’s 31.58 % negative EPS growth compared to $-0.19 earnings per share for last quarter.

Another two news for ChemoCentryx, Inc. (NASDAQ:CCXI) were recently brought out by: Finance.Yahoo.com on June 14, 2018 with title “4 Top-Ranked Nasdaq Stocks That Have Doubled This Year”. The other Globenewswire.com‘s article was titled “ChemoCentryx to Present at Two Upcoming Investor Conferences” and brought out on May 30, 2018.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

A total of 3 analysts rate ChemoCentryx (NASDAQ:CCXI) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. The firm has $20 highest and $16 lowest target. The avg target $17.67 is 35.20% above the last ($13.07) price. (NASDAQ:CCXI) has 3 ratings reports on Jun 27, 2018 according to StockzIntelligence. On Tuesday, March 13 the rating was maintained by JP Morgan with “Overweight”.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: